Home › Acute myeloïde leukemie › Pennsylvania › Philadelphia
Acute myeloïde leukemie klinische studies in Philadelphia, PA
34 studies voor Acute myeloïde leukemie zoeken deelnemers op locaties in en rond Philadelphia (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Thomas Jefferson University Hospital, Philadelphia
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruterenFase 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
RekruterenFase 1
- Children's Hospital of Philadelphia, Philadelphia
Assessment of Geriatric Evaluations Impact on New AML Guidance
RekruterenObservatieonderzoek
- Abramson Cancer Center at University of Pennsylvania, Philadelphia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Reading Hospital McGlinn Cancer Institute at Phoenixville, Phoenixville · 22 mijl verwijderd
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruterenObservatieonderzoek
- Children's Hospital of Philadelphia, Philadelphia
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RekruterenFase 3
- Thomas Jefferson University, Philadelphia
- Fox Chase Cancer Center, Philadelphia
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Thomas Jefferson University Hospital, Philadelphia
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RekruterenFase 3
- Children's Hospital of Philadelphia, Philadelphia
- Saint Christopher's Hospital for Children, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · 25 mijl verwijderd
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
RekruterenFase 1/2
- University of Pennsylvania, Philadelphia
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
RekruterenFase 1
- UPENN Perelman Center for Advanced Medicine, Philadelphia
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
RekruterenFase 3
- Children's Hospital of Philadelphia, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · 25 mijl verwijderd
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekruterenFase 1/2
- Children's Hospital of Philadelphia, Philadelphia
- Saint Christopher's Hospital for Children, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · 25 mijl verwijderd
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RekruterenFase 3
- Children's Hospital of Philadelphia, Philadelphia
- Nemours Alfred I. Dupont Hospital for Children, Wilmington · 25 mijl verwijderd
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RekruterenFase 3
- University of Pennsylvania, Philadelphia
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
RekruterenFase 2/3
- University of Pennsylvania, Philadelphia
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
RekruterenFase 1
- Children's Hospital of Philadelphia, Philadelphia
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
RekruterenFase 2
- Penn Medicine Abramson Cancer Center, Philadelphia
CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
RekruterenFase 1
- University of Pennsylvania, Philadelphia
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
Rekruteren
- Children's Hospital of Philadelphia, Philadelphia
CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
RekruterenFase 1
- Children's Hospital of Philadelphia, Philadelphia
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruterenObservatieonderzoek
- Children's Hospital of Philadelphia, Philadelphia
- Nemours - Alfred I. duPont Hospital for Children, Brandywine · 21 mijl verwijderd
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RekruterenFase 1/2
- Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
RekruterenFase 1
- University of Pennsylvania, Philadelphia
Massage Impact on Sleep in Pediatric Oncology
Rekruteren
- Children's Hospital of Philadelphia, Philadelphia
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekruterenFase 1/2
- Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Phase IB/II of CPX-351 for Relapse Prevention in AML
RekruterenFase 1/2
- University of Pennsylvania, Philadelphia
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
RekruterenFase 1
- Thomas Jefferson University Hospital, Philadelphia
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RekruterenFase 1
- Hospital of the University of Pennsylvania, Philadelphia
Tazemetostat and Palbociclib With CPX-351for R/R AML
RekruterenFase 1
- Thomas Jefferson University Hospital, Philadelphia
Home Blood Transfusions
Rekruteren
- Thomas Jefferson University Hospital, Philadelphia
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
RekruterenGezonde vrijwilligers welkom
- University of Pennsylvania, Philadelphia
Acute myeloïde leukemie studies in andere steden
- Houston, TX85 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Seattle, WA41 studies
- Baldwin Park, CA40 studies
- Columbus, OH35 studies
- Durham, NC33 studies
- Atlanta, GA31 studies
- Tampa, FL29 studies
- Chicago, IL26 studies
- Portland, OR25 studies
- Washington, DC24 studies
Andere studies in Philadelphia
- Kanker (alle vormen)59 studies
- Borstkanker56 studies
- Niet-kleincellige longkanker51 studies
- Metastatische kanker46 studies
- Prostaatkanker44 studies
- Colorectale kanker44 studies
- Eierstokkanker44 studies
- Longkanker36 studies
- Hartfalen31 studies
- Endometriumkanker28 studies
- Depressie26 studies
- Aldermeesklierkanker26 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.